Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer
Journal of Surgical Oncology · 2026
DOI: 10.1002/jso.70287 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Surgical Oncology, 2026. Verfasst von Camille C Baumrucker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Breast Neoplasms, Immunotherapy, Triple Negative Breast Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Immunotherapy is a growing treatment option for challenging breast cancer (BC) subtypes. Systemic administration can have significant adverse events (AEs), prompting interest in intratumoral injection. We evaluated the safety and feasibility of intratumoral injections at our institution.
Methods
This is an IRB‐approved retrospective review of neoadjuvant patients who received intratumoral talimogene laherparepvec (TVEC) (NCT02779855) for triple negative breast cancer (TNBC), dendritic cells (DC1) for HER2+ (NCT05325632), HER2 + /ER‐ (NCT03387553), or TNBC (NCT05504707), or Voyager V1 virus (VV1) (NCT01042379) for high‐risk lesions on ISPY2. This study outlines the safety and feasibility of intratumoral injections assessed by AEs, adherence to therapy, and ultrasound guidance.
Results
The study included 111 female patients (mean age 51; range 26‐80). Forty‐seven (42.3%) received TVEC, 62 (55.9%) received DC1, and 2 (1.8%) received VV1. Three patients missed one injection; 110 patients had ultrasound‐guided injections. Mean neoadjuvant therapy length was 172 days (range 127‐244). Local AEs included pain (20.7%), injection site reaction (27.9%), and hematoma (5.4%). Systemic AEs were reported more frequently, most commonly chills (52.3%), headache (39.6%), and fever (36.8%).
Discussion
Intratumoral IT injection is a viable treatment option that may minimize systemic exposure while maintaining therapeutic efficacy. Breast surgeons can play a role in intratumoral IT in BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
ORCID-Profile: Camille C Baumrucker
Zitieren
APA
Baumrucker, C. C., Harris, N., Aiello, P., Whiting, J., Sun, W., Soliman, H., Han, H., Costa, R., Czerniecki, B. J., & Lee, M. C. (2026). Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70287
Vancouver
Baumrucker CC, Harris N, Aiello P, Whiting J, Sun W, Soliman H, et al. Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70287
BibTeX
@article{Baumrucker2026,
author = {Baumrucker, Camille C and Harris, Nicole and Aiello, Paige and Whiting, Junmin and Sun, Weihong and Soliman, Hatem and Han, Hyo and Costa, Ricardo and Czerniecki, Brian J and Lee, Marie Catherine},
title = {Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer},
journal = {Journal of Surgical Oncology},
year = {2026},
doi = {10.1002/jso.70287}
}
EUVIMED